12407 N. MOPAC EXPY., AUSTIN, TX
Rein Therapeutics Enters $6 Million Pre-Paid Advance Agreement with Yorkville
Receives European Regulatory Approval to Initiate Phase 2 Trial of LTI-03 in Idiopathic Pulmonary Fibrosis
Other Events
News
Wins U.K. Approval to Launch Phase 2 Clinical Trial of LTI-03 in Idiopathic Pulmonary Fibrosis
News, Legal Opinion, Material Contracts
Shareholder votes
News, Articles of Incorporation
Q1
Amended Annual Report
FY 2024
Notice of Late Filing for Annual Report
Q3
Q2
FY 2023 amended
Effectiveness Notice
S-1
Prospectus filed pursuant to Rule 424(b)(5)
Registration Statement for Securities Offered under a Shelf Registration
Additional Proxy Materials
Definitive Proxy Statement
Statement of Changes in Beneficial Ownership
Initial Statement of Beneficial Ownership
Free Writing Prospectus
Correspondence
Submission Upload